- Report
- April 2024
- 146 Pages
Global
From €7661EUR$7,950USD£6,590GBP
- Report
- January 2024
- 175 Pages
Global
From €4722EUR$4,900USD£4,061GBP
- Report
- October 2023
- 184 Pages
Global
From €4722EUR$4,900USD£4,061GBP
- Report
- April 2024
- 185 Pages
Global
From €4722EUR$4,900USD£4,061GBP
- Report
- October 2023
- 78 Pages
United States
From €3373EUR$3,500USD£2,901GBP
- Report
- April 2024
- 185 Pages
From €4722EUR$4,900USD£4,061GBP
- Report
- November 2023
- 77 Pages
Germany
From €3373EUR$3,500USD£2,901GBP
- Report
- January 2022
- 200 Pages
Global
From €7227EUR$7,500USD£6,217GBP
- Book
- November 2018
- 464 Pages
Corneal Dystrophy is a group of inherited disorders that affect the cornea, the clear outer layer of the eye. It is characterized by the presence of abnormal deposits of proteins, lipids, and other substances in the cornea. Symptoms of Corneal Dystrophy can include blurred vision, sensitivity to light, and eye pain. Treatment options for Corneal Dystrophy include corneal transplantation, corneal cross-linking, and corneal inlays.
The Optical market for Corneal Dystrophy is focused on providing treatments and technologies to improve the vision of those affected by the disorder. Companies in this market are developing treatments and technologies to improve the quality of life of those affected by Corneal Dystrophy. These companies include Alcon, Bausch + Lomb, Johnson & Johnson Vision, and CooperVision. Show Less Read more